Innovating Works

Hypo-RESOLVE

Financiado
Hypoglycaemia REdefining SOLutions for better liVEs
Diabetes is one of the most prevalent global non-communicable diseases, affecting 60 million people in Europe, 10% of whom with type 1 diabetes. Normalising elevated glucose levels decreases symptoms, prevents microvascular compl... Diabetes is one of the most prevalent global non-communicable diseases, affecting 60 million people in Europe, 10% of whom with type 1 diabetes. Normalising elevated glucose levels decreases symptoms, prevents microvascular complications, improves cardiovascular health and saves lives, but creates a significant risk for hypoglycaemia when insulin treatment is required. Hypoglycaemia is a serious event associated with cognitive decline, reduced quality of life, cardiovascular events and mortality. Hypoglycaemia remains the principal barrier to achieve glucose levels necessary to prevent diabetic complications of chronic hyperglycaemia. The overall objective of Hypo-RESOLVE is to alleviate the burden and consequences of hypoglycaemia, to be achieved by answering several key questions through a unique public-private partnership. Hypo-RESOLVE will construct secure sustainable databases with data from 100-150 clinical trials offering huge statistical power to establish the glucose threshold(s) below which hypoglycaemia constitutes a risk for poor outcomes in various populations. This will provide valuable input for an evidence based classification of hypoglycaemia to be adopted by regulators, patient organisations and other stakeholders, for application in future trials, the clinic and epidemiologic studies. The basic science and translational research line of Hypo-RESOLVE will advance our understanding on mechanisms underlying consequences of hypoglycaemia and explore novel pathways for the restoration of impaired awareness of hypoglycaemia. Finally, we will determine the significance of CGM-detected low glucose and investigate psychological and economic impacts of hypoglycaemia to quantify the burden of hypoglycaemia both for the individual and next-of-kin, as well as for society. Altogether, Hypo-RESOLVE will importantly further our knowledge of hypoglycaemia, (facilitate to) reduce its burden and contribute to a better life for patients with insulin-treated diabetes ver más
31/10/2023
RADBOUDUMC
27M€
Duración del proyecto: 66 meses Fecha Inicio: 2018-04-30
Fecha Fin: 2023-10-31

Línea de financiación: concedida

El organismo H2020 notifico la concesión del proyecto el día 2023-10-31
Línea de financiación objetivo El proyecto se financió a través de la siguiente ayuda:
IMI2-2016-10-01: Understanding hypoglycaemia: the underlying mechanisms and addressing clinical determinants as well as consequences for people with diabetes by combining databases from clinical trials
Cerrada hace 7 años
Presupuesto El presupuesto total del proyecto asciende a 27M€
Líder del proyecto
STICHTING RADBOUD UNIVERSITAIR MEDISCH CENTRU... No se ha especificado una descripción o un objeto social para esta compañía.
Perfil tecnológico TRL 4-5